SEC Form 4
Altimmune, Inc. (ALT) insider trading
In the 12 months to Oct 26, 2026, 6 ALT insiders reported open-market purchases of $370.0K across 11 filings; no open-market sales were filed.
Latest filing · Last 12 months · Source: SEC EDGAR · How we count
- Open-market sales
- $0
- 0 filings · 0 insiders
- Open-market purchases
- $370.0K
- 11 filings
Who traded ALT, and when
- Purchase
ALT daily close from Oct 27, 2025 to Oct 26, 2026, between $2.06 and $6.18, last $2.06. 0 sale and 11 purchase filings by 6 insiders, marked at their filing dates. Jerome Benedict Durso, Director → President and CEO: bought $213.7K across 4 filings, first filed Dec 22, 2025, last Aug 13, 2026. John Gill, Director: bought $82.6K across 2 filings, first filed Dec 23, 2025, last Apr 6, 2026. Gregory L. Weaver, Chief Financial Officer: bought $49.2K across 2 filings, first filed Mar 9, 2026, last Apr 1, 2026. Wayne Pisano, Director: bought $20.4K across 1 filing, first filed Jan 9, 2026, last Jan 9, 2026. Catherine A. Sohn, Director: bought $2.1K across 1 filing, first filed Jan 5, 2026, last Jan 5, 2026. Diane Jorkasky, Director: bought $2.0K across 1 filing, first filed Dec 29, 2025, last Dec 29, 2025.
Largest mark · tap a row for others
Jerome Benedict Durso · President and CEO
Purchase $70,790
20,000 shares at $3.54 avg
Filed Mar 9, 2026 · traded Mar 6
Close on filing date $3.88
Jerome Benedict Durso · Director → President and CEO
Director → President and CEO
$213.7K boughtJohn Gill · Director
Director
$82.6K boughtGregory L. Weaver · Chief Financial Officer
Chief Financial Officer
$49.2K boughtWayne Pisano · Director
Director
$20.4K boughtCatherine A. Sohn · Director
Director
$2.1K boughtDiane Jorkasky · Director
Director
$2.0K boughtOpen-market trades
11 filings in the last 12 months| Insider | Role | Sold | Bought | Filings | Pre-arranged (10b5-1) | Last filed |
|---|---|---|---|---|---|---|
| Jerome Benedict Durso | Director → President and CEO | — | $213.7K | 4 | — | |
| John Gill | Director | — | $82.6K | 2 | — | |
| Gregory L. Weaver | Chief Financial Officer | — | $49.2K | 2 | — | |
| Wayne Pisano | Director | — | $20.4K | 1 | — | |
| Catherine A. Sohn | Director | — | $2.1K | 1 | — | |
| Diane Jorkasky | Director | — | $2.0K | 1 | — |
| Filed | Insider | Type | Shares | Avg price | Value | Held after | Source |
|---|---|---|---|---|---|---|---|
traded | Jerome Benedict Durso President and CEO | Purchase | 15,000 | $2.95 | $44.3K | 62,500 | |
traded | John Gill Director | Purchase | 9,200 | $3.41 | $31.3K | 21,700 | |
traded | Gregory L. Weaver Chief Financial Officer | Purchase | 10,000 | $3.15 | $31.5K | 38,078 | |
traded | Jerome Benedict Durso President and CEO | Purchase | 15,000 | $3.14 | $47.1K | 47,500 | |
traded | Gregory L. Weaver Chief Financial Officer | Purchase | 5,000 | $3.54 | $17.7K | 28,078 | |
traded | Jerome Benedict Durso President and CEO | Purchase | 20,000 | $3.54 | $70.8K | 32,500 | |
traded | Wayne Pisano Director | Purchase | 5,000 | $4.08 | $20.4K | 13,498 | |
traded | Catherine A. Sohn Director | Purchase | 500 | $4.24 | $2.1K | 1,500 | |
traded | Diane Jorkasky Director | Purchase | 527 | $3.80 | $2.0K | 527 | |
traded | John Gill Director | Purchase | 12,500 | $4.10 | $51.2K | 12,500 | |
traded | Jerome Benedict Durso Director | Purchase | 12,500 | $4.13 | $51.6K | 12,500 |
GET /stocks/filings/vX/form-4?tickers=ALT&filing_date.gte=2025-10-26&sort=filing_date.desc&limit=500{
"status": "OK",
"results": [
{
"tickers": [
"ALT"
],
"issuer_cik": "0001326190",
"owner_cik": "0001698665",
"accession_number": "0001698665-26-000007",
"form_type": "4",
"filing_date": "2026-08-13",
"period_of_report": "2026-08-13",
"issuer_name": "Altimmune, Inc.",
"issuer_trading_symbol": "ALT",
"owner_name": "Durso Jerome Benedict",
"is_director": true,
"is_officer": true,
"is_ten_percent_owner": false,
"is_other": false,
"officer_title": "President and CEO",
"security_type": "non_derivative",
"record_type": "transaction",
"security_title": "Common Stock, par value $0.0001",
"transaction_timeliness": "O",
"aff_10b5_one": false,
"transaction_date": "2026-08-13",
"transaction_code": "P",
"equity_swap_involved": false,
"transaction_shares": 15000,
"transaction_price_per_share": 2.95,
"transaction_acquired_disposed": "A",
"shares_owned_following_transaction": 62500,
"transaction_value": 44250,
"direct_or_indirect": "D"
},
{
"tickers": [
"ALT"
],
"issuer_cik": "0001326190",
"owner_cik": "0001409939",
"accession_number": "0001409939-26-000002",
"form_type": "4",
"filing_date": "2026-04-06",
"period_of_report": "2026-04-06",
"issuer_name": "Altimmune, Inc.",
"issuer_trading_symbol": "ALT",
"owner_name": "GILL JOHN",
"is_director": true,
"is_officer": false,
"is_ten_percent_owner": false,
"is_other": false,
"security_type": "non_derivative",
"record_type": "transaction",
"security_title": "Common Stock, par value $0.0001",
"transaction_timeliness": "O",
"aff_10b5_one": false,
"transaction_date": "2026-04-06",
"transaction_code": "P",
"equity_swap_involved": false,
"transaction_shares": 9200,
"transaction_price_per_share": 3.4076,
"transaction_acquired_disposed": "A",
"shares_owned_following_transaction": 21700,
"transaction_value": 31349.92,
"direct_or_indirect": "D",
"footnotes": [
{
"id": "F1",
"description": "The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.4050 to $3.4080, inclusive. The reporting person undertakes to provide to Altimmune, Inc., any security holder of Altimmune, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote."
}
]
}
]
}
// trimmed to 2 resultsThe response includes every Form 4 record; this page keeps open-market purchases and sales on common stock and removes duplicate joint-filer rows.
Other insider activity (not market trades) · 33 records
- Option exercises14 records
- Tax withholding14 records
- Grants and awards5 records
Reported on Form 4 but not purchases or sales in the market, so not counted in the totals above.
How to read this page
- Open-market purchase or sale
- A buy or sell of the company's stock at market price. Grants, option exercises, shares withheld for tax, gifts and employee stock plan purchases are listed separately and not counted.
- Role
- The title on each filing. Someone whose title changed shows more than one.
- Filing date
- Insiders have two business days to report a trade. Totals and the chart use the filing date, when the trade became public.
Frequently asked questions
Has Altimmune, Inc.'s CEO sold stock?
No. Jerome Benedict Durso (CEO) made no open-market sales filed as CEO in the last 12 months.
How current is ALT’s insider data?
These are ALT Form 4 filings from the last year, refreshed daily. The Massive Form 4 API has the full, continuously updated record.
What counts as an open-market buy or sell?
Only purchases and sales at the market price. Option exercises, grants, gifts, and shares withheld for taxes are reported on Form 4 but are left out of the buy and sell totals.
Build with AI
Track ALT insider trades with your agent
This page joins two Massive endpoints: Form 4 filings and daily prices. Ask an agent to watch for new filings:
Using the Massive API (massive.com/docs/llms.txt), check Form 4 filings for ALT every day with transaction_code=P and tell me when an insider files an open-market purchase, with their role, shares, price and the filing link.
Nothing on this page is investment advice. All data and content is provided for informational purposes under our Terms of Service.